Role of Cannabinoid CB2 Receptor in Alcohol Use Disorders: From Animal to Human Studies.
Por:
García-Gutiérrez MS, Navarrete F, Gasparyan A, Navarro D, Morcuende Á, Femenía T and Manzanares J
Publicada:
25 may 2022
Ahead of Print:
25 may 2022
Resumen:
Cumulative evidence has pointed out cannabinoid CB2 receptors (CB(2)r) as a potential therapeutic key target for treating alcohol use disorder (AUD). This review provides the most relevant results obtained from rodent and human studies, including an integrative section focused on the involvement of CB(2)r in the neurobiology of alcohol addiction. A literature search was conducted using the electronic databases Medline and Scopus for articles. The search strategy was as follows: "Receptor, Cannabinoid, CB2" AND "Alcohol-Related Disorders" AND "human/or patients"; "Receptor, Cannabinoid, CB2" AND "Alcohol" OR "Ethanol" AND "rodents/or mice/or rats". Pharmacological approaches demonstrated that the activation or blockade of CB(2)r modulated different alcohol-addictive behaviors. Rodent models of alcoholism revealed significant alterations of CB(2)r in brain areas of the reward system. In addition, mice lacking CB(2)r (CB(2)KO) show increased alcohol consumption, motivation, and relapse alterations. It has been stressed that the potential neurobiological mechanisms underlying their behavioral effects involve critical elements of the alcohol reward system. Interestingly, recent postmortem studies showed CNR2 alterations in brain areas of alcoholic patients. Moreover, although the number of studies is limited, the results revealed an association between some genetic alterations of the CNR2 and an increased risk for developing AUD. This review provides evidence that CB(2)r may play a role in alcohol addiction. Clinical studies are necessary to figure out whether CB(2)r ligands may prove useful for the treatment of AUD in humans.
Filiaciones:
:
Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
Red Primaria de Adicciones, Instituto de Salud Carlos III, MICINN and FEDER, 28029 Madrid, Spain
Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Centro de Diagnóstico 5ª Planta (Edf. Gris), Avda. Pintor Baeza 12, 03010 Alicante, Spain
:
Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
Red Primaria de Adicciones, Instituto de Salud Carlos III, MICINN and FEDER, 28029 Madrid, Spain
Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Centro de Diagnóstico 5ª Planta (Edf. Gris), Avda. Pintor Baeza 12, 03010 Alicante, Spain
:
Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
Red Primaria de Adicciones, Instituto de Salud Carlos III, MICINN and FEDER, 28029 Madrid, Spain
Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Centro de Diagnóstico 5ª Planta (Edf. Gris), Avda. Pintor Baeza 12, 03010 Alicante, Spain
:
Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
Red Primaria de Adicciones, Instituto de Salud Carlos III, MICINN and FEDER, 28029 Madrid, Spain
Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Centro de Diagnóstico 5ª Planta (Edf. Gris), Avda. Pintor Baeza 12, 03010 Alicante, Spain
Morcuende Á:
Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
:
Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
:
Instituto de Neurociencias, Universidad Miguel Hernández-CSIC, Avda de Ramón y Cajal s/n, San Juan de Alicante, 03550 Alicante, Spain
Red Primaria de Adicciones, Instituto de Salud Carlos III, MICINN and FEDER, 28029 Madrid, Spain
Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Centro de Diagnóstico 5ª Planta (Edf. Gris), Avda. Pintor Baeza 12, 03010 Alicante, Spain
gold, Green Published
|